Allevinix

1 x 100 ml

Active substance

Flunixin (Flunixin meglumine) : 50 mg/ml

ATC code

QM01AG90 Flunixine

QM01AG Fenamates

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Cattle, pigs and horses.

Indications

Cattle:

- Alleviation of clinical signs of respiratory disease when used concurrently with appropriate anti-infective therapy.

Pigs:

- To support appropriate antibiotic therapy in the treatment of Mastitis-Metritis-Agalactia syndrome.

- Alleviation of fever associated with respiratory disease when used in conjunction with specific antibiotic therapy.

Horses:

- Alleviation of inflammation and pain associated with musculo-skeletal disorders.

- Alleviation of visceral pain associated with colic.

Dose to be administered and administration route

Cattle: intramuscular and intravenous uses

Pigs: intramuscular use

Horses: intravenous use

The body weight should be accurately determined before the administration

Cattle:

2 mg of flunixin per kg bodyweight, equivalent to 2 ml of solution per 50 kg bodyweight, administered once daily by intravenous or intramuscular injection for 1 to 3 consecutive days.

Volumes greater than 20 ml should be divided and administered at least at 2 different injection sites.

Pigs:

To support appropriate antibiotic therapy in the treatment of Mastitis-Metritis-Agalactia syndrome:

2 mg of flunixin per kg bodyweight, equivalent to 2 ml of solution per 50 kg bodyweight, administered once daily for 1 to 3 consecutive days.

Alleviation of fever associated with respiratory diseases:

2 mg of flunixin per kg bodyweight, equivalent to 2 ml of solution per 50 kg bodyweight, administered once daily.

Maximum dosage volume per injection site should not exceed 5 ml. Volumes greater than 5 ml should be divided and administered at different injection sites.

Horses:

Alleviation of inflammation and pain associated with musculo-skeletal disorders:

1 mg of flunixin per kg bodyweight, equivalent to 1 ml of solution per 50 kg bodyweight, administered once daily for 1 to 5 consecutive days.

Alleviation of visceral pain associated with colic:

1 mg of flunixin per kg bodyweight, equivalent to 1 ml of solution per 50 kg bodyweight, administered once daily. Treatment may be repeated once or twice if colic recurs.

The cap can be broached up to 10 times. When treating large groups of animals at one time, use an automatic dosing device.

Adverse reactions

Cattle:

Rare

(1 to 10 animals / 10,000 animals treated):

Anaphylaxis (with collapse)^¹, death¹

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Bleeding^², gastrointestinal irritation², gastric ulceration², vomiting², renal function impairment²

Undetermined frequency

Renal and hepatic disorders⁴

Delayed parturition⁵, increase of stillbirths⁵, retained placenta⁶

¹mainly during rapid intravenous injection

² mainly in dehydrated or hypovolaemic animals

³ following intramuscular injection

⁴ idiosyncratic effects, as with other non-steroidal anti-inflammatory drugs

⁵ through a tocolytic effect by inhibiting prostaglandins that are important in signalling the initiation of parturition

⁶ in cases of the use of the veterinary medicinal product in the immediate post-partum period

Horses:

Rare

(1 to 10 animals / 10,000 animals treated):

Anaphylaxis (with collapse)¹, death¹

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Bleeding², gastrointestinal irritation², gastric ulceration², vomiting², renal function impairment²

Undetermined frequency

Renal and hepatic disorders^³

Delayed parturition^⁴, increase of stillbirths⁴, retained placenta^⁵

Pigs:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Bleeding¹, gastrointestinal irritation¹, gastric ulceration¹, vomiting¹, renal function impairment¹

Undetermined frequency

Renal and hepatic disorders²

Delayed parturition³, increase of stillbirths³, retained placenta⁴

¹ mainly in dehydrated or hypovolaemic animals

² idiosyncratic effects, as with other non-steroidal anti-inflammatory drugs

³ through a tocolytic effect by inhibiting prostaglandins that are important in signalling the initiation of parturition

⁴ in cases of the use of the veterinary medicinal product in the immediate post-partum period

In case of untowards effects stop treatment and seek medical advice.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the section “Contact details” of the package leaflet for respective contact details.